Photon Counting Computed Tomography Market Size, Share and Trends Analysis, By Detector Type, By Technology (Photon Counting CT Systems, Spectral CT / Multienergy CT Systems, and Hybrid Photon Counting Solutions), By Application (Clinical and Research), By End-Use, and By Region, Forecast 2026-2033

Photon Counting Computed Tomography Market Overview and Key Insights:

Photon counting computed tomography market size reached USD 87.3 million in 2025 and is expected to register a revenue CAGR of 27.7% during the forecast period. Photon-counting computed tomography (PCCT) is a novel sophisticated imaging technique that will revolutionize the traditional clinical use of computed tomography (CT). Photon-counting detectors divide the number of photons and incident X-ray energy spectrum into several energy bins.

Market Drivers:

Rising prevalence of chronic disorders is a key driver driving the market revenue growth. According to the Centre of Disease Control and Prevention (CDC), in the United States heart disease is the top cause of mortality for men, women, and people of most racial and ethnic groups. Cardiovascular disease claims one life every 34 seconds. Cardiovascular disease claimed 919,032 lives in 2023. That amounts to one out of every three fatalities. In 2023, persons under 65 accounted for around 1 in 6 fatalities from cardiovascular diseases (CVDs). In the United States, someone has a heart attack every 40 seconds. Every year, roughly 805,000 people in the United States experience a heart attack. Of these, 605,000 are a first heart attack, and 200,000 happen to be persons who have already had a heart attack.

The introduction of PCDs is a noteworthy development in the field of non-invasive cardiovascular imaging, which has advanced significantly during the previous few decades. PCCT offers various advantages over standard CT systems, including higher spatial resolution, improved signal and contrast characteristics, lower electronic noise, decreased radiation exposure, and multi-energy capabilities. These benefits have shown encouraging results in the quantification of coronary calcium, myocardial extracellular volume, myocardial radiomics characteristics, and epicardial and pericoronary adipose tissue, as well as in the qualitative evaluation of coronary plaques and stents.

On March 2025, Siemens Healthineers has secured FDA clearance for its Naeotom Alpha line of photon-counting CT scanners. This product family now includes the Naeotom Alpha.Pro, the second dual-source CT system, and the Naeotom Alpha.Prime, the world’s first single-source photon-counting CT scanner. The original dual-source model, now renamed the Naeotom Alpha.Peak, will continue as the flagship system within the Naeotom Alpha portfolio.

Market Opportunity:

Integration of AI and machine learning acts as opportunities for photon counting computed tomography market. Integration of cutting-edge artificial intelligence (AI) with PCD-CT is poised to change tumor imaging further. Deep learning reconstruction (DLR) techniques, for instance, may considerably reduce image noise while keeping spatial resolution, beyond the capabilities of standard iterative reconstruction algorithms. This synergistic combination between modern detection technology and AI holds great promise to boost picture quality and diagnostic confidence in lung tumor evaluation, paving the path for more precise and individualized oncology therapy.

Enhanced spatial resolution and reduced blooming artifacts may improve the delineation of lesion boundaries, internal heterogeneity, and subtle characteristics, such as bronchovascular invasion. These advances are particularly essential for image-based staging and therapy planning in lung cancer. Furthermore, it is becoming more widely acknowledged that high-fidelity input data is essential for radiomics and AI-based prediction models.

On November 2025, Royal Philips, a global leader in health technology, has announced the release of Verida, the world’s first detector-based spectral CT powered entirely by AI. This represents a watershed moment in CT, with AI optimizing the entire imaging chain reducing system noise, improving image quality, and expediting clinical workflow. Philips Verida achieves industry-leading spectral picture quality with minimal noise by integrating AI across the imaging chain, from acquisition to reconstruction, in addition to high-definition conventional images.

Recent Trends:

Emerging trends include development of next-generation semiconductor detectors, Ultra-High-Resolution (UHR) Imaging, AI integration in photon counting CT, development of K-edge imaging & novel contrast agents, and multi-energy & spectral imaging expansion.

Spectral CT imaging has evolved steadily, gaining momentum when dual-energy CT entered clinical use about two decades ago. Although manufacturers differ in detector design, X-ray source, reconstruction methods, and other technical choices, all systems allow radiologists to leverage tissue-specific energy characteristics through virtual monochromatic imaging and material decomposition into components such as water and iodine.

A key advantage of PCD-CT is its ability to deliver higher image quality at lower radiation doses. By precisely capturing the energy of individual photons, photon-counting detectors improve tissue differentiation, offering superior spatial and contrast resolution compared with traditional dual-energy EID-based systems, which depend mainly on enhanced spectral imaging performance.

Restraints & Challenges:

One of the most significant drawbacks is the high expense of PCCT systems, both in terms of hardware and continuous maintenance. The cost of creating modern semiconductor detectors, cooling systems, and high-speed electronics is much higher than that of standard CT scanners. As a result, only a few hospitals have installed PCCT devices, which are often used for research or specialized applications. This limits equitable access and causes delays in broader clinical validation in general hospital settings.

Another problem is the vast volume of picture data produced by PCCT. PCDs can detect and store energy-specific photon information, resulting in data sets that are several times bigger than those of EID-CT. The huge data size may put a significant strain on Picture Archiving and Communication Systems (PACS) and hospital data networks that were not initially built to manage such high-throughput imaging procedures.

Detector Type Segment Insights and Analysis:

Based on the detector type, photon counting computed tomography market is segmented into silicon-based photon counting detectors, Cadmium Telluride (CdTe) detectors, Cadmium Zinc Telluride (CZT) detectors, Gallium Arsenide (GaAs) detectors, and others.

Cadmium Telluride (CdTe) segment contributed the largest market share in 2025. Cadmium telluride (CdTe) is a semiconductor material capable of directly converting X-rays into electric signal pulses. Each entering X-ray quantum generates clouds of free charge carriers, the amount of which is proportional to the energy of the incident X-ray beam. The most common semiconductor materials are cadmium telluride (CdTe), cadmium zinc telluride (CZT), and silicon (Si). While the CdTe/CZT detector has short pulse outputs and allows for pixel size miniaturization, both of which help to mitigate pile-up effects, the intricate fabrication process of CdTe/CZT crystals presents challenges, including high production difficulties and a low yield of high-quality products.

On August 2025, Vital Materials has officially introduced the VITA Genesis, China’s entirely unique Photon Counting CT (PCCT) scanner, ushering global medical imaging technology into the “Quantum Flux” sensing age and enabling Chinese innovation in precise diagnoses and treatment. Currently, PCCT detectors generally use three materials: Cadmium Zinc Telluride (CdZnTe or CZT), Cadmium Telluride (CdTe), and deep silicon.

Technology Segment Insights and Analysis:

Based on the technology, photon counting computed tomography market is segmented into photon counting CT systems, spectral CT / multienergy CT systems, and hybrid photon counting solutions.

Photon counting CT systems segment contributed the largest market share in 2025. Photon-counting CT easily distinguishes between tissue types and contrast agents using spectral CT with improved virtual non-contrast images and measurements, providing the exact concentration of materials within the voxel (e.g., calcium, iodine), resulting in improved accuracy of perfusion and ventilation measurements, kidney stone characterization, and so on.

The literature has accumulated evidence supporting the numerous benefits of PCCT for various clinical applications. These advantages stem from the unique properties of PCDs, which are composed of semiconductor materials capable of directly turning photons into electric signals. The most significant developments in PCCT are better spatial resolution, noise reduction, and spectral characteristics.

On November 2024, Canon Inc., Canon Medical Systems Corporation, and Canon Healthcare USA, Inc. announced a research collaboration with Penn Medicine for the application of photon-counting CT technology, following the completion of the world’s fourth Canon-developed photon-counting CT system at the Hospital of the University of Pennsylvania. Canon’s PCCT features a one-of-a-kind detector made of cadmium zinc telluride. The addition of zinc to cadmium telluride improves the detector’s ability to catch photons and dose efficiency. The collaboration will concentrate on improving certain diagnostic imaging specializations, including chest/cardiac and musculoskeletal imaging.

Application Segment Insights and Analysis:

Based on the application, photon counting computed tomography market is segmented into clinical applications and research applications.

Clinical applications segment contributed the largest market share in 2025. It is further sub segmented into Cardiology, Oncology, Neurology, Orthopedics, Pulmonology, and Gastroenterology. CT systems with photon-counting detectors (PCDs), also known as photon-counting CT (PCCT), are transforming imaging in a variety of subspecialties, including cardiac, vascular, thoracic, and musculoskeletal radiology. These advantages stem from the unique properties of PCDs, which are composed of semiconductor materials capable of directly turning photons into electric signals. The most significant developments in PCCT are better spatial resolution, noise reduction, and spectral characteristics. PCCT spatial resolution of 0.25 mm enables better imaging of small structures (e.g., small arteries, artery walls, distal bronchi, and bone trabeculations) and their diseases, as well as the detection of previously undetectable anomalies.

In addition, blooming artifacts from calcifications, stents, and other thick structures are minimized. The spectrum capabilities of PCCT provide numerous benefits, including reduced radiation and contrast material exposure for patients. Furthermore, many forms of information can be derived from a single data set, including quantitative data, which is commonly used as a substitute for functional information.

On December 2025, Siemens Healthineers has announced Syngo.CT Coronary Cockpit, a new software solution for the Syngo.via2 platform that supports the management of coronary artery disease (CAD) in both dual-source and photon-counting CT scanners. The integration of the Syngo.CT Coronary Cockpit with Siemens Healthineers’ dual-source and photon-counting CT scanners allows for high native temporal resolution while also supporting clinical accuracy and operational efficiency across the CAD pathway.

Geographical Outlook:

Photon counting computed tomography market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Photon Counting Computed Tomography Market:

North America is registered to have highest market share in photon counting computed tomography market in 2025. Rising rates of cancer and cardiovascular disease, along with advances in detector materials and computing architectures, primarily drive this growth. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, an estimated 226,650 people will receive a lung cancer diagnosis in 2025. One in every 16 individuals will develop lung cancer during their lifetime—affecting one in 17 women and one in 16 men. Smoking accounts for roughly 80% of lung cancer deaths. Although about 8 million Americans qualify for lung cancer screening, only around 16% undergo the recommended evaluations.

On April 2023, AnX Robotica, a pioneer in enhanced gastrointestinal visualization technology, has received the FDA approval of NaviCam ProScan. The FDA approved ProScan through the rigorous De Novo Submission Process, making it the first AI-Assisted Reading Tool developed to assist small bowel capsule endoscopy reviewers for adult patients who had capsule endoscopy images taken for suspected small intestine hemorrhage. ProScan software, an artificial intelligence (AI)-assisted reading tool, uses cutting-edge technology to transform the area of gastroenterology.

Asia Pacific Photon Counting Computed Tomography Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by rising prevalence of cancer and cardiovascular diseases, growing shift toward personalized and precision medicine, and rising demand for spectral CT imaging in research institutes. Japan has the world’s oldest population, with an average life expectancy of 81 years for males and 87 for women. Noncommunicable diseases (NCDs) are common in this super-aged society, accounting for more than half of all fatalities in Japan. As of 2022, Japan’s overall lung cancer incidence was 30.5 cases per 100,000 people, with a 14.2 death rate per 100,000 people. Regionally, Japan is leading cancer research efforts aimed at finding and treating the most common malignancies in the Asia Pacific region, recognizing that the region cannot rely on Europe or the United States to address region-specific anomalies and rare diseases.

On November 2022, Canon Medical Systems Corporation, a subsidiary of Canon Inc., has developed the first domestically manufactured photon-counting CT (PCCT) system that incorporates Redlen’s sophisticated technologies. This system was deployed at Japan’s National Cancer Center (NCC) Exploratory Oncology Research & Clinical Trial Center, where it is currently being utilized to perform research on PCCT’s clinical applications. The modular detector can handle a wide range of investigations and is expected to meet the most stringent criteria of advanced clinical practice.

Competition Analysis:

Photon counting computed tomography market is characterized by a consolidated structure, with few players competing across various segments and regions. List of major players included in photon counting computed tomography market report are:

• Siemens Healthineers AG
• GE HealthCare
• Canon Medical Systems Corporation
• Kromek Group plc
• NeuroLogica Corp.
• Neusoft Medical Systems
• Dunlee (Koninklijke Philips N.V.)
• Detection Technology Plc

Strategic Developments in Photon Counting Computed Tomography Market:

• In August 2025, the National Medical Products Administration of China (NMPA) has approved Neusoft Medical Systems’ NeuViz P10 photon-counting CT for market use. This is the first photon-counting CT approved in China and the world’s first wide-body system with an 8-cm detector. To optimize therapeutic and scientific value, the NeuViz P10 combines four innovative platforms: NeuPhoton Counting, Photon Supersonic, Photon Intelligence, and Photon scientific. Together, these technologies provide faster scans, safer imaging, intelligent workflow assistance, and new prospects for clinical research.
• In January 2023, NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced a collaboration with the University of Dundee in Scotland, United Kingdom, to conduct research using the OmniTom Elite with Photon Counting Detector (PCD) computed tomography (CT) imaging technology. The OmniTom Elite with PCD is a significant innovation in CT technology, created in-house by the NeuroLogica research and development team in Danvers, Massachusetts, in partnership with Samsung.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2023 to 2024, with 2025 serving as the base year for market size calculations. The forecast period extends from 2026 to 2033.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of Photon Counting Computed Tomography Market Report:

Photon Counting Computed Tomography market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2023-2024 and revenue forecasts for 2026-2033 across the following segments:

• Detector Type Outlook (Revenue, USD Million; 2023-2033)
  • Silicon-Based Photon Counting Detectors
  • Cadmium Telluride (CdTe) Detectors
  • Cadmium Zinc Telluride (CZT) Detectors
  • Gallium Arsenide (GaAs) Detectors
  • Others

• Technology Outlook (Revenue, USD Million; 2023-2033)
  • Photon Counting CT Systems
  • Spectral CT / Multienergy CT Systems
  • Hybrid Photon Counting Solutions

• Application Outlook (Revenue, USD Million; 2023-2033)
  • Clinical Applications
    • Cardiology
    • Oncology
    • Neurology
    • Orthopedics
    • Pulmonology
    • Gastroenterology
  • Research Applications
    • Preclinical imaging
    • Drug discovery & pharmacology
    • Material decomposition studies

• End-Use Outlook (Revenue, USD Million; 2023-2033)
  • Hospitals
  • Diagnostic Imaging Centers
  • Research & Academic Institutions
  • Government and Defense Healthcare Facilities

• Regional Outlook (Revenue, USD Million; 2023-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about Photon Counting Computed Tomography market report